Brought to you by 
Immunocore, Ltd.
http://www.immunocore.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Immunocore, Ltd.
Finance Watch: Multiple VC Mega-Rounds Fund T-Cell, Hearing, IO, Fibrosis Therapies
Private Company Edition: Immunocore’s $130m round kicked off a series of $100m-plus venture capital deals, including financings for Xilio, Akouos and Pliant. Also, VC investment in cell and gene therapies surged in 2019 and MPM launched two funds with $126 for early cancer research.
Troubled Immunocore Reawakens With New $130m Funding
After a record breaking Series A fundraising, the UK biotech hit a series of problems. Can a new CEO and new funding help it fulfil its promise?
Woodford Woes Drag On For Immunocore
Once seen as the champion of biotech start-ups, Woodford’s blind faith has shackled firms to unrealistic valuations.
UK Biotech Ervaxx Launches With Focus On ‘Dark Antigens’
Melanoma is first target for company developing cancer vaccines and T-cell receptor immunotherapies.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
-
Large Molecule